Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
CRB-913 Presentation: Corbus Pharmaceuticals will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, during a webcast on December 11, 2025.
Obesity Treatment Challenges: Obesity is a significant global health issue with few safe pharmacological options; previous CB1 inverse agonists were withdrawn due to neuropsychiatric side effects.
CRB-913's Safety Profile: CRB-913 is designed to be a second-generation CB1 inverse agonist with reduced brain penetration, showing a 15-fold lower brain penetration compared to monlunabant and a 50 times lower brain:plasma ratio than rimonabant.
Financial Status: As of September 30, 2025, Corbus had $104 million in cash and investments, with a recent public offering expected to extend its cash runway into 2028; the stock is currently trading at $11.82, up 15.20%.
Get Free Real-Time Notifications for Any Stock
Analyst Views on CRBP
About CRBP
About the author
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
